Utilização de sílica mesoporosa como adjuvante em vacinas de vesícula de membrana externa de Neisseria meningitidis / Application of mesoporous silica as a vaccine adjuvant in the outer membrane vesicles vaccination of Neisseria meningitidis


IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia




Outer membrane vesicles or OMV are nanoparticles released into the culture medium during bacterial growth resulting from evaginations of the outer membrane. The OMV consists of antigens present in the bacterial outer membrane, like porins and lipooligosaccharides - LOS, these structures provide an immuno-stimulatory effect, and potential target for vaccine production. This study aimed to analyze the use OMV of Neisseria meningitidis IAL2443, belonging to serogroup B strain causing meningitis in São Paulo, as vaccine using the mesoporous silica SBA-15 and SBA-16 in the immunization process. Fermentation process was used in semi-solid state for bacterial growth and a process of ultracentrifugation for the isolation these OMV. It was compared to OMV production of strains of N.meningitidis strains IAL 2443 and C2135, and knock-out mutant for the gene responsible for producing pilin - C2135_pilE. The immunological activity was measured by immunization in Swiss mice and verification of cytotoxicity was performed in cell culture using VERO cells and NIH 3T3. The results showed that different strains of N. meningitidis have OMVs kinetics of production of different time and quantity. The expression does not pile also affects the kinetics of production of these structures. The use of adjuvants mesoporous silica SBA-15 and SBA-16 with the IAL2443 OMV increases the recognition by the immune system, thus bringing the number of specific antibodies against the same bacterial strain and other strains of the same serotype and different serotypes. The cytotoxicity test in NIH 3T3 cells showed VERO and safety in preparation adjuvanted with SBA-15 and SBA-16, confirming the safe use of these preparations as vaccine adjuvants. The study showed that the methodology used for the production of OMV is advantageous from the point of view of quantity and cost and use of SBA-15 and SBA-16 has potential as an adjuvant in vaccines based on OMV.


neisseria meningitidis vacinas bacterianas nanopartículas adjuvantes farmaceuticos meningite bacteriana neisseria meningitidis bacterial vacines nanoparticles pharmaceutic adjuvants bacterial meningitis

Documentos Relacionados